Latest Headlines

  1. Helix Launches 23,000-Patient Clinico-Genomic Cohort For Autoimmune Diseases To Advance Drug Discovery And Development 3/18/2025

    Helix, a leader in population genomics and precision health, is announcing a new comprehensive clinico-genomic virtual registry of autoimmune disease patients. Consisting of over 23,000 individuals with conditions such as Lupus, Rheumatoid Arthritis (RA), Psoriasis, Multiple Sclerosis (MS), Hashimoto's disease, Crohn's and many more, it's one of the largest autoimmune cohorts in the world.

  2. Valo Health And nference Announce Long-Term Partnership To Accelerate Human-Centric Drug Discovery And Development 3/18/2025

    Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable.

  3. Precision BioSciences Announces Clearance Of Investigational New Drug Application By The U.S. FDA For First-In-Class PBGENE-HBV Designed To Eliminate Root Cause Of Chronic Hepatitis B 3/17/2025

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV.

  4. Xeris Announces Approval Of Supplemental New Drug Application (sNDA) Of Gvoke VialDx (Glucagon) For Use As A Diagnostic Aid 3/17/2025

    Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

  5. Taiho Pharmaceutical To Acquire Next-Generation ADC Drug Discovery Company Araris Biotech 3/17/2025

    Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced today that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris (hereinafter "the Acquisition").

  6. China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA Approval Of SYCUME For The Treatment Of Thyroid Eye Disease 3/14/2025

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China.

  7. Salipro Biotech And Boehringer Ingelheim Enter Research And License Agreement To Accelerate Multiple Boehringer Ingelheim Pipeline Programs 3/13/2025

    Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets.

  8. LGM Pharma Invests $6M In U.S. Drug Manufacturing Capabilities For Liquids, Suspensions, Semi-Solids, And Suppositories 3/12/2025

    LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6M to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.

  9. Annovis Joins Experts At Drug Development Summit To Redefine Parkinson's Treatment 3/11/2025

    Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA.

  10. Sarcomatrix Therapeutics Announces Strategic Collaboration With RNA Advisors To Advance Drug Development Strategy 3/11/2025

    Sarcomatrix Therapeutics, a biopharmaceutical company pioneering novel treatments for muscular dystrophies and age-related muscle degeneration, today announced a strategic collaboration withRNA Advisors, a leading life sciences advisory firm specializing in valuation, strategy, and transaction support.